Overview
Atrogi is a clinical-stage biopharmaceutical company headquartered in Stockholm, Sweden, focused on developing first-in-class small-molecule therapeutics targeting metabolic disorders. The company's lead candidate, ATR-258, is a GRK-biased β2-adrenergic receptor agonist designed to promote fat loss while preserving muscle mass, addressing type 2 diabetes and obesity through a novel mechanism that mimics the metabolic effects of exercise. Atrogi's approach targets the underlying pathophysiology of metabolic disease by modulating GPCR signaling pathways, with a broader pipeline addressing muscle-wasting conditions and related metabolic complications.